Idexx Laboratories, Inc [IDXX] stock prices are up 8.95% to $471.38 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The IDXX shares have gain 6.89% over the last week, with a monthly amount glided 12.62%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Idexx Laboratories, Inc [NASDAQ: IDXX] stock has seen the most recent analyst activity on December 02, 2024, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $500. Previously, BTIG Research started tracking the stock with Buy rating on July 25, 2024, and set its price target to $580. On January 30, 2024, downgrade downgraded it’s rating to Neutral but maintained its price target of $525 on the stock. Exane BNP Paribas started tracking the stock assigning a Outperform rating and suggested a price target of $602 on December 07, 2023. Cleveland Research upgraded its rating to a Buy. Atlantic Equities downgraded its rating to Neutral for this stock on August 02, 2023, but kept the price target unchanged to $610. In a note dated July 25, 2022, Stifel downgraded an Hold rating on this stock but restated the target price of $415.
The stock price of Idexx Laboratories, Inc [IDXX] has been fluctuating between $356.14 and $548.88 over the past year. Currently, Wall Street analysts expect the stock to reach $479.75 within the next 12 months. Idexx Laboratories, Inc [NASDAQ: IDXX] shares were valued at $471.38 at the most recent close of the market. An investor can expect a potential return of 1.78% based on the average IDXX price forecast.
Analyzing the IDXX fundamentals
The Idexx Laboratories, Inc [NASDAQ:IDXX] reported sales of 3.90B for trailing twelve months, representing a surge of 5.84%. Gross Profit Margin for this corporation currently stands at 0.61% with Operating Profit Margin at 0.29%, Pretax Profit Margin comes in at 0.29%, and Net Profit Margin reading is 0.23%. To continue investigating profitability, this company’s Return on Assets is posted at 0.28, Equity is 0.57 and Total Capital is 0.55. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.34.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 461.64 points at the first support level, and at 451.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 481.52, and for the 2nd resistance point, it is at 491.66.
Ratios To Look Out For
It’s worth pointing out that Idexx Laboratories, Inc [NASDAQ:IDXX]’s Current Ratio is 1.25. On the other hand, the Quick Ratio is 0.90, and the Cash Ratio is 0.14. Considering the valuation of this stock, the price to sales ratio is 9.80, the price to book ratio is 24.11 and price to earnings (TTM) ratio is 44.19.
Transactions by insiders
Recent insider trading involved FENNELL GEORGE, Executive Vice President, that happened on Feb 10 ’25 when 9986.0 shares were sold. Officer, FENNELL GEORGE completed a deal on Feb 10 ’25 to buy 9966.0 shares. Meanwhile, Director SZOSTAK M ANNE sold 3000.0 shares on Feb 07 ’25.
